Inmune Bio, Inc. — Director's Dealing 2024

Apr 24, 2024

SEC Form 4/A — Form 4/A

Issuer: Inmune Bio, Inc. (INMB)
CIK: 0001711754
Period of Report: 2024-04-19

Reporting Person: Juda Scott (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2024-04-19	Common Stock	P	29603	$8.32	Acquired	66603	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2024-04-19	Common Stock Warrants (right to buy)	$9.152	P	29603	Acquired		Common Stock (29603)	Direct

Footnotes

F1: The common shares and warrants reported on this Form 4 were purchased in a registered direct offering at a price of $8.445, for an aggregate purchase price of $249,997.34 pursuant to a securities purchase agreement dated April 19, 2024. The warrants are exercisable immediately upon issuance until the earlier of (i) the two year anniversary of the initial exercise date or (ii) thirty trading days following the reporting of the top line data (EMACC) in the Phase 2 Alzheimer's program of XPro1595, (the "Termination Date") but not thereafter, provided however, in the event that the Warrant is held by directors, officers or other affiliates of the Company and the Termination Date is during a period that such officers, directors or affiliates are subject to a blackout with respect to trading in the Company's common stock, such officers, directors or affiliates will have an additional 60 days from the termination of the blackout date to exercise the Warrant.